GS Group, IMM Investment to jointly bid for Hugel Korean conglomerate emerging as frontrunner to acquire botox maker
이 기사는 2021년 08월 11일 08:01 더벨 유료페이지에 표출된 기사입니다.South Korean conglomerate GS Group has teamed up with private equity firm IMM Investment to jointly bid for Bain Capital-owned botox maker Hugel, industry sources said on Monday.
The US buyout firm and BoA-Merrill Lynch, which is managing the sale process, are in talks separately with potential buyers seeking to acquire a controlling stake in Hugel. Among them are a consortium of GS Group and IMM Investment, Chinese strategic investors and private equity firms, according to sources.
The GS consortium is viewed as the strongest candidate to win the race. In contrast with Shinsegae Group which withdrew from the deal last month, GS Group has opted to join forces with IMM Investment which will lead the consortium. This indicates the conglomerate’s strong interest in the pharmaceutical company, industry watchers said.
“The GS-IMM Investment consortium is emerging as the frontrunner to acquire Hugel,” an industry insider said. “It is unlikely that the seller will select a Chinese firm as the preferred buyer for several reasons.”
The South Korean pharmaceutical company is selling through a limited auction process. Another industry insider said, “Who will win the race remains to be seen because all bidders in the race have strong desire to acquire the company.”
The sale method was changed from a private sale to a limited auction as the stake sale attracted interest from many domestic and overseas investors. Bain reportedly intends to skip the preliminary round of bidding and receive binding offers from a select group of potential buyers.
Founded in 2001, Hugel is the country’s largest player in the market for botulinum toxin products by market share. The company went public on Kosdaq in 2015 and has since grown rapidly. Its consolidated revenue increased to a record of 211 billion won ($183.8 million) in 2020, compared to 182 billion won in 2017. Full-year 2021 revenue is projected to surpass 270 billion won.
Bain acquired a 44.4% stake in Hugel in 2017 for about 927.5 billion won. Bain’s holding in the botox maker is estimated to be worth about 2 trillion won including a control premium. (Reporting by Ha-na Suh)
최신뉴스 in 전체기사
- 에스엘바이오닉스, 수산화리튬 판매 사업 첫발
- 수확의 계절 맞은 신성이엔지, CE·RE 사업부 날개
- [건설사 시공능력 점검]두산건설, 최대주주 변경 후 재무개선 '눈길'
- 일레븐건설, 1조 유엔사부지 개발 승인 임박
- HDC현대산업개발, 첫 분양 앞두고 주가 꿈틀…경영 정상화 기대감
- [건설리포트]코오롱글로벌, 분할 앞두고 건설부문 성장세 '주춤'
- KH그룹, KLPGA 투어 '대학생 디자인 공모전' 개최
- 다올인베, 스케일업펀드 2000억 모았다
- [IPO 모니터]쏘카 주주들 ‘평가절하’ 수용...일등공신 '롯데렌탈'
- [VC 투자기업]급성장 오늘식탁, '정산시스템' 정비한다
Translated by Ryu Ho-joung 의 다른 기사 보기
더벨 서비스 문의
02-724-4102유료 서비스 안내